All episodes

New markers in precision hematology: circulating tumor cells and cell-free DNA as peripheral markers of hematological disease, new markers in flow cytometry to differentiate aberrant cells from normal ones and to study the tumor microenvironment, extracellular vesicles as risk markers for the disease.

Therapeutic resistance and the risks of progression remain an ongoing challenge for various hematological malignancies, including acute promyelocytic leukemia, chronic myeloproliferative neoplasms, myelodysplastic syndromes, and acute myeloid leukemia.